Type Private Headquarters Lachen, Switzerland Number of locations 45 Founded 1983 | Website www.octapharma.com Revenue 1.6 billion EUR (2016) Founder Wolfgang Marguerre Number of employees 7,094 | |
 | ||
Industry Pharmaceutical Industry Products octaplas, octagam,octagam10%, octanate, octanineF, octaplex, octavi SD Optimum, octalbin, uniplas, rhesonativ, aunativ, gammonativ, atenativ, gammanorm, nanotiv, octonativ, octanine F, nuwiq, wilate
See complete products listing. Motto For the safe and optimal use of human proteins | ||
Octapharma AG is the largest privately owned human protein products manufacturer in the world. Founded in 1983 by Wolfgang Marguerre, Octapharma employs 6,213 people globally. Octapharma is owned by Wolfgang Marguerre and his three children, two of whom, Frederic Marguerre and Tobias Marguerre, sit on the management board. Octapharma's core business is the development and production of human proteins from human blood plasma and human cell-lines. It is headquartered in Lachen, Switzerland.
Contents
Products
Patients in 113 countries are treated with products in the following therapeutic areas:
History
Octapharma was founded in 1983 on the principle of enhancing safety for patients. In the name Octapharma, the “octa” is derived from the Greek word for eight, named after the factor which is deficient in haemophilia A patients. Octapharma’s inaugural product was the first Factor VIII concentrate using what was then innovative solvent detergent virus inactivation technology.
The underlying principle of Octapharma’s R&D is the development of therapies based on human proteins either purified from human plasma or produced by recombinant technologies applied to human cell lines.
Research and Development
Current R&D Projects (April 2014)
Production
Octapharma converts source plasma into plasma protein products through fractionation and processing. Octapharma owns five state-of-the-art production facilities in Austria, France, Germany, Sweden and Mexico.
Octapharma owns plasma centres in Europe and the United States. To fulfil increasing global demand and to exceed its goals, the company is increasing plasma availability by sourcing higher volumes of plasma and increasing the capacity of production plants to convert more source plasma into product.